Aphria Inc. continues to work its magic in the growing cannabis industry. As a global leader in cannabis expansion, it has successfully completed the first shipment of its certified European Union Good Manufacturing Practices (EU GMP) dried flower product, marking another milestone for the company. The shipment was made from the company’s Aphria One EU GMP facility to CC Pharma GmbH, its wholly-owned German subsidiary and a leading distributor of pharmaceutical products to more than 13,000 pharmacies in Germany.
Explains Aphria CEO Irwin D. Simon, “Our first EU GMP shipment into Germany represents another significant milestone for Aphria Inc., one that strengthens our position as a leading cannabis company in Germany and in the European Union.” He added, “We are leveraging our strong medical platform and multi-faceted German strategy, which combines domestic cultivation, import licenses and large distribution infrastructure, to increase access to high-quality medical cannabis for patients worldwide. We remain excited about future milestones, including the completion of our cultivation facility in Neumunster, Germany, which we expect will be completed in Q2 FY2021.”
The German market is often viewed as one of the most important markets for medical cannabis markets in the world, and Aphria has continued to develop a strong presence in the country. It has been introducing operations to facilitate the importation of EU-GMP-certified cannabis from its home country of Canada, and is creating supply chains to CC Pharma in order to leverage the latter’s expansive distribution network in Germany.
Aphria is based in Ontario, Canada, but has operations across the globe. One of its goals is to “set the standard for the low-cost production of high-quality cannabis at scale,” while developing new activity in previously untapped market segments using innovative technology. It has continued along those lines throughout all of 2020, introducing several new CBD-based wellness brands that have quickly become popular with consumers.